Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders

Journal of Clinical Psychiatry

Volumn 61, Issue 4, 2000, Pages 252-260

  McConville, Brian J ^a,d   Arvanitis, Lisa A ^b   Thyrum, Per T ^b   Yeh, Chiao ^b   Wilkinson, Lisa A ^b   Chaney, Robert O ^a   Foster, Keith D ^c   Sorter, Michael T ^c   Friedman, Loren M ^a   Brown, Kerri L ^a   Heubi, James E ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZATROPINE MESILATE; CARBAMAZEPINE; CHLORAL HYDRATE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLOZAPINE; DEXAMPHETAMINE; DIAZEPAM; FLUOXETINE; FLURAZEPAM; HALOPERIDOL; IMIPRAMINE; LITHIUM; LORAZEPAM; OLANZAPINE; PARACETAMOL; PAROXETINE; PEMOLINE; PEMOLINE MAGNESIUM; PERPHENAZINE; PHENYTOIN; PROCYCLIDINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MALE; PRIORITY JOURNAL; PSYCHOSIS; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0034071578     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n0403     Document Type: Article

References (40)

1. Loranger AW. Sex differences in age at onset of schizophrenia. Arch Gen Psychiatry 1984;41:157-161
2. Hafner H, Riecher-Rossler A, Maurer K, et al. First onset and early symptomatology of schizophrenia: a chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci 1992;242:109-118
3. Beratis S, Gabriel J, Hoidas S. Age at onset in subtypes of schizophrenic disorders. Schizophr Bull 1994;20:287-296.
4. Campbell M, Grega DM, Green WH, et al. Neuroleptic induced dyskinesias in children. Clin Neuropharmacol 1983;6:207-222
5. Gualtieri CT, Quade D, Kicks RE, et al. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 1984;141:20-23
6. Whitaker A, Rao U. Neuroleptics in pediatric psychiatry. Psychiatr Clin North Am 1987;15:243-276
7. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1987;48(9, suppl):13-19
8. Masi G. Atypical neuroleptics in the treatment of early onset schizophrenia. Panminerva Med 1997;39:215-221
9. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
10. Juul Povlsen U, Noring U, Rog R, et al. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-185
11. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273
12. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
13. Birmaher B, Baker R, Kapur S, et al. Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1992; 31:160-164
14. Frazier JA, Gordon CT, McKenna K, et al. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994;33:658-663
15. Remschmidt H, Schulz E, Martin PDM. An open trial of clozapine in thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 1994;4:31-34
16. Kumra S, Frazier JA, Jacobsen KL, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-1097
17. Grcevich SJ, Findling RL, Schulz SC, et al. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 1996;6:251-257
18. Kumra S, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998;37:377-385
19. Mandoki MW. Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects. J Child Adolesc Psychopharmacol 1995;5:49-67
20. Goldstein JM, Arvanitis LA. ICI 204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic: review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Rev 1995;1:50-73
21. Fabre LF Jr, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical anti-psychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17:366-378
22. Borison RL, Arvanitis L, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169
23. Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
24. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
25. Seroquel [package insert]. Wilmington, Del: Zeneca Pharmaceuticals; 1998
26. Grimm SW, Stams KR, Bui K. In vitro prediction of potential metabolic drug interactions for Seroquel [abstract]. Schizophr Res 1997;24:200
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press; 1994
28. Lingjarerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):1-100
29. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;45(212):11-19
30. AIMS. In: Guy W. ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health 1976:534-537
31. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
32. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
33. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health 1976;218-222
34. Andreasen N. Modified Scale for the Assessment of Negative Symptoms. NIMH Treatment Strategies in Schizophrenia Study. US Dept Health Human Services publication (ADM) 9-102. Washington, DC: Public Health Administration; 1984
35. Wong JY, Ewing BJ, Thyrum PT, et al. Effects of haloperidol, risperidone and thioridazine on the pharmacokinetics of quetiapine. Presented at the New Clinical Drug Evaluation Unit meeting: May 27-30, 1997; Boca Raton, Fla
36. Arvanitis LA, Rak IW. Efficacy, safety, and tolerability of "Seroquel" (quetiapine) in elderly subjects with psychotic disorders [abstract]. Schizophr Res 1997;24:196
37. Juncos JL, Evatt ML, Jewart D. Long-term effects of quetiapine fumarate in Parkinsonism complicated by psychosis [abstract]. Neurology 1998;50 (suppl 4):A70
38. May PR, Tuma AH, Yale C, et al. Schizophrenia: a follow-up study of results of treatment, II: hospital stay over two to five years. Arch Gen Psychiatry 1976;33:481-486
39. Crow TJ, MacMillan JF, Johnson AL, et al. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-127
40. Loebel AD, Liebermann JA, Alvir JMJ, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149: 1183-1188